Bariatric Surgery and Pharmacokinetics Fluoxetine: BAR-MEDS Fluoxetine

What this Trial Is About

This research aims to understand how bariatric surgery, such as gastric bypass and sleeve gastrectomy, affects the way the body processes fluoxetine, a medication commonly prescribed for depression. Changes in stomach acidity, emptying time, and digestive enzyme activity after surgery may alter the availability of fluoxetine in the bloodstream. The study is observational and focuses on patients with morbid obesity preparing for these surgeries in Central Norway. Participants will continue their usual prescription of fluoxetine while the study monitors how the surgery influences its concentration in their blood over time. The main measurement is the area under the curve (AUC) of fluoxetine concentration in blood serum, tracked from before surgery up to one year afterwards. No experimental treatments or placebo groups are involved. During the study, participants undergo regular blood tests to measure fluoxetine levels. Researchers observe these changes without altering prescribed medication. The study is led by the Norwegian University of Science and Technology and involves adult Norwegian citizens aged 18 to 70 who are planning bariatric surgery. Participation lasts from baseline through one year post-surgery, focusing on medication processing changes after the operation.

Bariatric Surgery and Pharmacokinetics of Fluoxetine